{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T19:27:20Z","timestamp":1784402840099,"version":"3.55.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA171963"],"award-info":[{"award-number":["P50 CA171963"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32 HL007088"],"award-info":[{"award-number":["T32 HL007088"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32 GM007200"],"award-info":[{"award-number":["T32 GM007200"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["T32 HD007499"],"award-info":[{"award-number":["T32 HD007499"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy in which activating mutations in the Notch pathway are thought to contribute to transformation, in part, by activating c-Myc. Increased c-Myc expression induces oncogenic stress that can trigger apoptosis through the MDM2-p53 tumor suppressor pathway. Since the great majority of T-ALL cases carry inactivating mutations upstream in this pathway but maintain wildtype <jats:italic>MDM2<\/jats:italic> and <jats:italic>TP53<\/jats:italic>, we hypothesized that T-ALL would be selectively sensitive to MDM2 inhibition. Treatment with idasanutlin, an MDM2 inhibitor, induced only modest apoptosis in T-ALL cells but upregulated the pro-apoptotic BH3 domain genes <jats:italic>BAX<\/jats:italic> and <jats:italic>BBC3<\/jats:italic>, prompting us to evaluate the combination of idasanutlin with BH3 mimetics. Combination treatment with idasanutlin and navitoclax, a potent Bcl-2\/Bcl-xL inhibitor, induces more consistent and potent synergistic killing of T-ALL PDX lines in vitro than venetoclax, a Bcl-2 specific inhibitor. Moreover, a marked synergic response to combination treatment with idasanutlin and navitoclax was seen in vivo in all four T-ALL xenografts tested, with a significant increase in overall survival in the combination treatment group. Collectively, these preclinical data show that the combination of idasanutlin and navitoclax is highly active in T-ALL and may merit consideration in the clinical setting.<\/jats:p>","DOI":"10.1038\/s41375-023-02057-x","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T13:02:08Z","timestamp":1697288528000},"page":"2356-2366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7096-8602","authenticated-orcid":false,"given":"Kimberly B.","family":"Johansson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan S.","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna V.","family":"Dmytrenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3170-7581","authenticated-orcid":false,"given":"Daniel C.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,14]]},"reference":[{"key":"2057_CR1","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","volume":"26","author":"EA Raetz","year":"2008","unstructured":"Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children\u2019s Oncology Group Study. J Clin Oncol. 2008;26:3971\u20138.","journal-title":"J Clin Oncol"},{"key":"2057_CR2","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1080\/10428194.2018.1522442","volume":"60","author":"GS Guru Murthy","year":"2019","unstructured":"Guru Murthy GS, Pondaiah SK, Abedin S, Atallah E. Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. Leuk Lymphoma. 2019;60:1171\u20138.","journal-title":"Leuk Lymphoma"},{"key":"2057_CR3","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1200\/JCO.2003.10.116","volume":"21","author":"JM Goldberg","year":"2003","unstructured":"Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience. J Clin Oncol. 2003;21:3616\u201322.","journal-title":"J Clin Oncol"},{"key":"2057_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"AP Weng","year":"2004","unstructured":"Weng AP. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269\u201371.","journal-title":"Science."},{"key":"2057_CR5","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1182\/blood-2008-10-184069","volume":"113","author":"V Asnafi","year":"2009","unstructured":"Asnafi V, Buzyn A, Le Noir S, Baleydier F, Simon A, Beldjord K, et al. NOTCH1\/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009;113:3918\u201324.","journal-title":"Blood"},{"key":"2057_CR6","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1038\/leu.2009.64","volume":"23","author":"A Larson Gedman","year":"2009","unstructured":"Larson Gedman A, Chen Q, Kugel Desmoulin S, Ge Y, LaFiura K, Haska CL, et al. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. Leukemia. 2009;23:1417\u201325.","journal-title":"Leukemia."},{"key":"2057_CR7","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1200\/JCO.2009.22.0996","volume":"27","author":"MR Mansour","year":"2009","unstructured":"Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, Koo K, et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII\/ECOG E2993 protocol. J Clin Oncol. 2009;27:4352\u20136.","journal-title":"J Clin Oncol"},{"key":"2057_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1365-2141.2009.07607.x","volume":"145","author":"M-J Park","year":"2009","unstructured":"Park M-J, Taki T, Oda M, Watanabe T, Yumura-Yagi K, Kobayashi R, et al. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol. 2009;145:198\u2013206.","journal-title":"Br J Haematol"},{"key":"2057_CR9","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1182\/blood.V84.12.4038.bloodjournal84124038","volume":"84","author":"J Hebert","year":"1994","unstructured":"Hebert J, Cayuela J, Berkeley J, Sigaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood. 1994;84:4038\u201344.","journal-title":"Blood."},{"key":"2057_CR10","doi-asserted-by":"publisher","first-page":"24304","DOI":"10.1074\/jbc.M602596200","volume":"281","author":"M-S Dai","year":"2006","unstructured":"Dai M-S, Shi D, Jin Y, Sun X-X, Zhang Y, Grossman SR, et al. Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism. J Biol Chem. 2006;281:24304\u201313.","journal-title":"J Biol Chem"},{"key":"2057_CR11","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1101\/gad.13.20.2658","volume":"13","author":"CM Eischen","year":"1999","unstructured":"Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13:2658\u201369.","journal-title":"Genes Dev"},{"key":"2057_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/088800101753328466","volume":"18","author":"B Gustafsson","year":"2001","unstructured":"Gustafsson B, Axelsson B, Gustafsson B, Christensson B, Winiarski J. MDM2 and P53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors. Pediatr Hematol Oncol. 2001;18:497\u2013508.","journal-title":"Pediatr Hematol Oncol"},{"key":"2057_CR13","doi-asserted-by":"publisher","first-page":"a026286","DOI":"10.1101\/cshperspect.a026286","volume":"7","author":"EQ Comeaux","year":"2017","unstructured":"Comeaux EQ, Mullighan CG. TP53 mutations in hypodiploid acute lymphoblastic leukemia. Cold Spring Harb Perspect Med. 2017;7:a026286.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2057_CR14","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421\u20138.","journal-title":"Cancer Res"},{"key":"2057_CR15","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.1182\/blood-2011-12-400929","volume":"119","author":"D M\u00e9rino","year":"2012","unstructured":"M\u00e9rino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C, et al. Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood. 2012;119:5807\u201316.","journal-title":"Blood."},{"key":"2057_CR16","doi-asserted-by":"crossref","unstructured":"de Vos S, Leonard JP, Friedberg JW, Zain J, Dunleavy K, Humerickhouse R, et al. Safety and efficacy of navitoclax, a BCL-2 and BCL-X L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. Leuk Lymphoma. 2020;62:1\u20139.","DOI":"10.1080\/10428194.2020.1845332"},{"key":"2057_CR17","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson WH, O\u2019Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11:1149\u201359.","journal-title":"Lancet Oncol"},{"key":"2057_CR18","first-page":"891","volume":"49","author":"J Minowada","year":"1972","unstructured":"Minowada J, Onuma T, Moore GE. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst. 1972;49:891\u20135.","journal-title":"J Natl Cancer Inst"},{"key":"2057_CR19","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.","journal-title":"Sci Signal"},{"key":"2057_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"2057_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","volume":"37","author":"K Clement","year":"2019","unstructured":"Clement K, Rees H, Canver MC, Gehrke JM, Farouni R, Hsu JY, et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat Biotechnol. 2019;37:224\u20136.","journal-title":"Nat Biotechnol"},{"key":"2057_CR22","doi-asserted-by":"publisher","first-page":"e154092","DOI":"10.1172\/JCI154092","volume":"132","author":"J-C Yao","year":"2022","unstructured":"Yao J-C, Oetjen KA, Wang T, Xu H, Abou-Ezzi G, Krambs JR, et al. TGF-\u03b2 signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche. J Clin Investig. 2022;132:e154092.","journal-title":"J Clin Investig"},{"key":"2057_CR23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1182\/blood.2021010762","volume":"139","author":"JT Warren","year":"2022","unstructured":"Warren JT, Cupo RR, Wattanasirakul P, Spencer DH, Locke AE, Makaryan V, et al. Heterozygous variants of CLPB are a cause of severe congenital neutropenia. Blood. 2022;139:779\u201391.","journal-title":"Blood."},{"key":"2057_CR24","doi-asserted-by":"publisher","first-page":"587096","DOI":"10.3389\/fcell.2021.587096","volume":"9","author":"JA Dom\u00ednguez-Bautista","year":"2021","unstructured":"Dom\u00ednguez-Bautista JA, Acevo-Rodr\u00edguez PS, Castro-Obreg\u00f3n S. Programmed cell senescence in the mouse developing spinal cord and notochord. Front Cell Dev Biol. 2021;9:587096.","journal-title":"Front Cell Dev Biol"},{"key":"2057_CR25","doi-asserted-by":"publisher","first-page":"e13832","DOI":"10.1111\/acel.13832","volume":"22","author":"C Ahire","year":"2023","unstructured":"Ahire C, Nyul-Toth A, DelFavero J, Gulej R, Faakye JA, Tarantini S, et al. Accelerated cerebromicrovascular senescence contributes to cognitive decline in a mouse model of paclitaxel (Taxol)-induced chemobrain. Aging Cell. 2023;22:e13832.","journal-title":"Aging Cell"},{"key":"2057_CR26","unstructured":"Mead R. The design of experiments: statistical principles for practical applications. Cambridge, England; New York: Cambridge University Press; 1988."},{"key":"2057_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose an interaction potency model. Comput Struct Biotechnol J. 2015;13:504\u201313.","journal-title":"Comput Struct Biotechnol J"},{"key":"2057_CR28","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48:W488\u201393.","journal-title":"Nucleic Acids Res"},{"key":"2057_CR29","doi-asserted-by":"crossref","unstructured":"Yee K. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: results from an idasanutlin phase 1\/1b study. Leuk Res. 2021;100:106489.","DOI":"10.1016\/j.leukres.2020.106489"},{"key":"2057_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2020-136419","volume":"136","author":"C Jamois","year":"2020","unstructured":"Jamois C, Anders D, Beckermann BM, Genevray M, Mundt K, Petry C, et al. Contribution of idasanutlin exposure to safety, pharmacodynamics and clinical response of patients with acute myeloid leukemia treated with idasanutlin + cytarabine in phase I and III studies. Blood. 2020;136:7\u20138.","journal-title":"Blood."},{"key":"2057_CR31","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","volume":"4","author":"TN Chonghaile","year":"2014","unstructured":"Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4:1074\u201387.","journal-title":"Cancer Discov"},{"key":"2057_CR32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-016-0280-3","volume":"9","author":"C Lehmann","year":"2016","unstructured":"Lehmann C, Friess T, Birzele F, Kiialainen A, Dangl M. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in P53 wild-type acute myeloid leukemia models. J Hematol Oncol. 2016;9:50.","journal-title":"J Hematol Oncol"},{"key":"2057_CR33","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","volume":"128","author":"SL Khaw","year":"2016","unstructured":"Khaw SL, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva RT, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood. 2016;128:1382\u201395.","journal-title":"Blood."},{"key":"2057_CR34","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11:1440\u201353.","journal-title":"Cancer Discov"},{"key":"2057_CR35","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/onc.2012.347","volume":"32","author":"W Vainchenker","year":"2013","unstructured":"Vainchenker W, Constantinescu SN. JAK\/STAT signaling in hematological malignancies. Oncogene. 2013;32:2601\u201313.","journal-title":"Oncogene."},{"key":"2057_CR36","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49:1211\u20138.","journal-title":"Nat Genet"},{"key":"2057_CR37","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1097\/HS9.0000000000000310","volume":"3","author":"D Verbeke","year":"2019","unstructured":"Verbeke D, Gielen O, Jacobs K, Boeckx N, De Keersmaecker K, Maertens J, et al. Ruxolitinib synergizes with dexamethasone for the treatment of T-cell acute lymphoblastic leukemia. HemaSphere. 2019;3:e310.","journal-title":"HemaSphere"},{"key":"2057_CR38","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41375-021-01392-1","volume":"36","author":"S Yuan","year":"2022","unstructured":"Yuan S, Wang X, Hou S, Guo T, Lan Y, Yang S, et al. PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression. Leukemia. 2022;36:370\u201382.","journal-title":"Leukemia."},{"key":"2057_CR39","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","volume":"62","author":"TYJ Appeldoorn","year":"2023","unstructured":"Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL, Touw DJ. Pharmacokinetics and pharmacodynamics of ruxolitinib: a review. Clin Pharmacokinet. 2023;62:559\u201371.","journal-title":"Clin Pharmacokinet"},{"key":"2057_CR40","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/ajh.26935","volume":"98","author":"T Kong","year":"2023","unstructured":"Kong T, Yu L, Laranjeira ABA, Fisher DAC, He F, Cox MJ, et al. Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms. Am J Hematol. 2023;98:1029\u201342.","journal-title":"Am J Hematol"},{"key":"2057_CR41","doi-asserted-by":"crossref","unstructured":"Pui C-H. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166\u201378.","DOI":"10.1056\/NEJMra052603"},{"key":"2057_CR42","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2005.04.5856","volume":"24","author":"PS Gaynon","year":"2006","unstructured":"Gaynon PS, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Hawks R, et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children\u2019s Oncology Group Study CCG-1941. J Clin Oncol. 2006;24:3150\u20136.","journal-title":"J Clin Oncol"},{"key":"2057_CR43","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1182\/blood-2011-01-329441","volume":"118","author":"N Gokbuget","year":"2011","unstructured":"Gokbuget N, Basara N, Baurmann H, Beck J, Br\u00fcggemann M, Diedrich H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011;118:3504\u201311.","journal-title":"Blood."},{"key":"2057_CR44","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1172\/JCI61269","volume":"122","author":"P Van Vlierberghe","year":"2012","unstructured":"Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Investig. 2012;122:3398\u2013406.","journal-title":"J Clin Investig"},{"key":"2057_CR45","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1309\/AJCPMF03LVSBLHPJ","volume":"144","author":"MJ You","year":"2015","unstructured":"You MJ, Medeiros LJ, Hsi ED. T-lymphoblastic leukemia\/lymphoma. Am J Clin Pathol. 2015;144:411\u201322.","journal-title":"Am J Clin Pathol"},{"key":"2057_CR46","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","volume":"119","author":"GM Dores","year":"2012","unstructured":"Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012;119:34\u201343.","journal-title":"Blood."},{"key":"2057_CR47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/bmt.2016.194","volume":"52","author":"JE Brammer","year":"2017","unstructured":"Brammer JE, Saliba RM, Jorgensen JL, Ledesma C, Gaballa S, Poon M, et al. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transplant. 2017;52:20\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"2057_CR48","doi-asserted-by":"publisher","first-page":"18261","DOI":"10.1073\/pnas.0606108103","volume":"103","author":"T Palomero","year":"2006","unstructured":"Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci. 2006;103:18261\u20136.","journal-title":"Proc Natl Acad Sci"},{"key":"2057_CR49","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1101\/gad.1450406","volume":"20","author":"AP Weng","year":"2006","unstructured":"Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, et al. C-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia\/lymphoma. Genes Dev. 2006;20:2096\u2013109.","journal-title":"Genes Dev"},{"key":"2057_CR50","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1128\/MCB.01091-06","volume":"26","author":"VM Sharma","year":"2006","unstructured":"Sharma VM, Calvo JA, Draheim KM, Cunningham LA, Hermance N, Beverly L, et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-Myc. Mol Cell Biol. 2006;26:8022\u201331.","journal-title":"Mol Cell Biol"},{"key":"2057_CR51","doi-asserted-by":"publisher","first-page":"6650","DOI":"10.1182\/blood-2011-02-336842","volume":"117","author":"M Bonnet","year":"2011","unstructured":"Bonnet M, Loosveld M, Montpellier B, Navarro J-M, Quilichini B, Picard C, et al. Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. Blood. 2011;117:6650\u20139.","journal-title":"Blood."},{"key":"2057_CR52","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.cell.2013.05.041","volume":"153","author":"B King","year":"2013","unstructured":"King B, Trimarchi T, Reavie L, Xu L, Mullenders J, Ntziachristos P, et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell. 2013;153:1552\u201366.","journal-title":"Cell."},{"key":"2057_CR53","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1172\/JCI34616","volume":"118","author":"A Silva","year":"2008","unstructured":"Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, et al. PTEN posttranslational inactivation and hyperactivation of the PI3K\/Akt pathway sustain primary T cell leukemia viability. J Clin Investig. 2008;118:3762\u201374.","journal-title":"J Clin Investig"},{"key":"2057_CR54","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/nm1636","volume":"13","author":"T Palomero","year":"2007","unstructured":"Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13:1203\u201310.","journal-title":"Nat Med"},{"key":"2057_CR55","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2006.07.014","volume":"16","author":"CV Dang","year":"2006","unstructured":"Dang CV, O\u2019Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16:253\u201364.","journal-title":"Semin Cancer Biol"},{"key":"2057_CR56","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nature03845","volume":"436","author":"MT Hemann","year":"2005","unstructured":"Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, et al. Evasion of the P53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005;436:807\u201311.","journal-title":"Nature."},{"key":"2057_CR57","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1158\/0008-5472.CAN-18-2718","volume":"79","author":"C Morcelle","year":"2019","unstructured":"Morcelle C, Menoyo S, Mor\u00f3n-Duran FD, Tauler A, Kozma SC, Thomas G, et al. Oncogenic MYC induces the impaired ribosome biogenesis checkpoint and stabilizes P53 independent of increased ribosome content. Cancer Res. 2019;79:4348\u201359.","journal-title":"Cancer Res"},{"key":"2057_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93863-9","volume":"11","author":"S Zanotti","year":"2021","unstructured":"Zanotti S, Vanhauwaert S, Van Neste C, Olexiouk V, Van Laere J, Verschuuren M, et al. MYCN-induced nucleolar stress drives an early senescence-like transcriptional program in hTERT-immortalized RPE cells. Sci Rep. 2021;11:14454.","journal-title":"Sci Rep"},{"key":"2057_CR59","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","volume":"128","author":"KD Mason","year":"2007","unstructured":"Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128:1173\u201386.","journal-title":"Cell."},{"key":"2057_CR60","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","volume":"30","author":"AW Roberts","year":"2012","unstructured":"Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30:488\u201396.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02057-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02057-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02057-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T09:04:16Z","timestamp":1701075856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02057-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,14]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2057"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02057-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,14]]},"assertion":[{"value":"18 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}